RxDoctor Payments Data

Joseph Risser

Family Medicine · San Diego, CANPI 1952386765

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $8,187 of the $11,139 with a category attached, or 73.5%. Novo Nordisk AS accounts for 74.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $9,480 and has fallen 94.9% since, to $482 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,139in general payments, 2019–2025

Across 121 payments — averaging $92.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$8K
  • Novo Nordisk$2K
  • Amgen$152
  • Corcept Therapeutics$75
  • AstraZeneca$75
  • Hologic Sales And Service, LLC$70
  • plus $168 from 6 others
$633,646in research payments, 2019–2025

Across 1,968 payments — averaging $321.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$619K
  • Abbott$13K
  • AbbVie$2K

What the payments were for

  • Consulting fees$9458%
  • Travel & lodging$8,18773%
  • Food & beverage$2,00718%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,139 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide59$97,665
JardianceEmpagliflozin75$89,262
OzempicSemaglutide57$60,831
TrulicityDulaglutide36$52,260
Atrovent HfaIpratropium Bromide90$50,197
EliquisApixaban56$46,217
JanuviaSitagliptin Phosphate37$42,924
FarxigaDapagliflozin Propanediol30$37,265
XareltoRivaroxaban15$20,892
EntrestoSacubitril/Valsartan12$16,321
VascepaIcosapent Ethyl13$9,385
DuleraMometasone/Formoterol14$6,286
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$5,305
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,034
Albuterol Sulfate HfaAlbuterol Sulfate126$4,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$2,264$158,496116 claims
AstraZenecaFarxiga$75$37,26530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →